Suggestions

Du même auteur

Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report

Archive ouverte | Blay, J.Y. | CCSD

International audience. Imatinib mesylate is approved for the adjuvant treatment of KIT-positive gastrointestinal stromal tumor (GIST) following surgical resection. However, uncertainty remains in terms of patient e...

The value of research collaborations and consortia in rare cancers

Archive ouverte | Blay, J.Y. | CCSD

International audience. Rare cancers are defined by an incidence of less than six per 100 000 people per year. They represent roughly 20% of all human cancers and are associated with worse survival than are so-calle...

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

Archive ouverte | Nishida, T. | CCSD

International audience. Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therap...

Chargement des enrichissements...